Table 5.
Univariate analysis of prognostic factors for PFS and OS
| Factors | PFS | OS | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Age ≥ 60 years | 28.200 (11.219–45.182) | 0.676 | 28.000 (12.968–23.220) | 0.810 |
| Refractory disease | 27.105 (16.829–37.381) | 0.760 | 41.065 (30.193–51.937) | 0.883 |
| B symptoms present | 32.733 (20.102–45.365) | 0.622 | 41.011 (28.993–53.029) | 0.916 |
| ECOG PS (2–4) | 13.054 (8.234–17.875) | < 0.001* | 18.094 (12.968–23.220) | < 0.001* |
| Stage Ⅲ/Ⅳ | 22.628 (14.053–31.204) | 0.007* | 34.176 (24.978–43.375) | 0.007* |
| IPI (3–5) | 24.076 (14.868–33.283) | 0.104 | 33.625 (23.924–43.326) | 0.017* |
| Pretreatment EBV‐DNA positivity | 14.080 (9.140–19.019) | 0.006* | 26.937 (16.233–37.641) | < 0.001* |
| Post‐treatment EBV‐DNA positivity | 29.696 (22.240–37.152) | < 0.001* | 20.282 (6.502–34.063) | < 0.001* |
| Elevated LDH | 27.445 (16.437–38.453) | 0.698 | 36.816 (25.784–47.848) | 0.255 |
| Elevated β2‐microglobulin | 30.406 (19.872–36.780) | 0.866 | 37.667 (25.266–50.067) | 0.455 |
CI, confidence interval; EBV, Epstein‐Barr virus; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; IPI, International Prognostic Index; LDH, lactate dehydrogenase; OS, overall survival; PFS, progression‐free survival.
*
P < 0.05.